Rossari Biotech Financials
| ROSSARI Stock | 817.45 4.50 0.55% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 4.3 B | 4.1 B |
|
|
Rossari | Select Account or Indicator |
Understanding current and past Rossari Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Rossari Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Rossari Biotech's assets may result in an increase in income on the income statement.
Rossari Biotech Stock Summary
Rossari Biotech competes with Fineotex Chemical, Sumitomo Chemical, Ratnamani Metals, Thirumalai Chemicals, and Iris Clothings. Rossari Biotech is entity of India. It is traded as Stock on NSE exchange.Specialization | Basic Materials, Specialty Chemicals |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE02A801020 |
| Business Address | 201 A B, |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.rossari.com |
| Phone | 91 22 6123 3800 |
You should never invest in Rossari Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Rossari Stock, because this is throwing your money away. Analyzing the key information contained in Rossari Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Rossari Biotech Key Financial Ratios
Rossari Biotech's financial ratios allow both analysts and investors to convert raw data from Rossari Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Rossari Biotech over time and compare it to other companies across industries.| Revenue | 18.31 B | ||||
| Gross Profit | 3.74 B | ||||
| EBITDA | 2.57 B | ||||
| Net Income | 1.31 B | ||||
| Total Asset | 15.72 B |
Rossari Biotech Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.7B | 5.6B | 12.6B | 13.7B | 15.7B | 7.9B | |
| Other Current Liab | 111.1M | 190.7M | 157.1M | 1.1B | 1.3B | 1.4B | |
| Other Liab | 35.6M | 21.7M | 23.9M | 1.6B | 1.8B | 1.9B | |
| Net Tangible Assets | 1.2B | 2.8B | 4.0B | 5.4B | 6.3B | 6.6B | |
| Net Debt | 377.2M | (152.1M) | (290.5M) | 41.0M | 936.2M | 983.0M | |
| Retained Earnings | 1.6B | 2.4B | 3.3B | 4.4B | 5.6B | 5.9B | |
| Accounts Payable | 970.0M | 1.3B | 1.9B | 1.8B | 2.2B | 1.4B | |
| Cash | 292.1M | 152.1M | 374.8M | 698.3M | 251.7M | 254.9M | |
| Other Assets | 130.3M | 255.6M | 58.9M | 144.0M | 165.6M | 114.4M | |
| Net Receivables | 941.4M | 1.5B | 3.0B | (23.4M) | 4.3B | 4.5B | |
| Inventory | 581.7M | 953.5M | 1.9B | 1.9B | 2.8B | 3.0B | |
| Other Current Assets | 290.8M | 242.2M | 500.8M | 3.8B | 4.9B | 5.2B | |
| Total Liab | 1.8B | 1.5B | 4.5B | 4.5B | 5.2B | 2.8B | |
| Total Current Assets | 3.3B | 3.5B | 6.1B | 7.2B | 8.4B | 4.4B | |
| Short Term Debt | 313.4M | 53.9M | (714.9M) | 390.0M | 745.6M | 782.9M | |
| Intangible Assets | 47.7M | 107.6M | 1.7B | 1.5B | 1.4B | 1.5B | |
| Common Stock | 101.5M | 103.9M | 110.1M | 110.3M | 110.5M | 91.9M | |
| Long Term Debt | 6.7M | 339.6M | 0.0 | 349.3M | 333.2M | 349.9M | |
| Net Invested Capital | 3.5B | 4.1B | 8.1B | 9.9B | 11.5B | 6.2B | |
| Short Long Term Debt | 329.7M | 0.0 | 84.3M | 390.0M | 725.0M | 761.3M | |
| Net Working Capital | 1.8B | 2.0B | 3.1B | 3.7B | 4.2B | 2.5B | |
| Capital Stock | 101.5M | 103.9M | 110.1M | 110.3M | 110.5M | 106.4M |
Rossari Biotech Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 35.6M | 29.9M | 126.6M | 223.2M | 193.7M | 203.4M | |
| Total Revenue | 6.0B | 7.1B | 14.8B | 16.6B | 18.3B | 10.0B | |
| Gross Profit | 2.2B | 2.3B | 3.6B | 4.8B | 5.3B | 2.9B | |
| Operating Income | 879.6M | 1.0B | 1.3B | 1.5B | 4.1B | 4.3B | |
| Ebit | 916.2M | 1.1B | 1.5B | 1.5B | 2.0B | 1.1B | |
| Research Development | 53.5M | 75.0M | 59.5M | 82.6M | 70.2M | 63.0M | |
| Ebitda | 1.1B | 1.3B | 1.9B | 2.1B | 2.6B | 1.4B | |
| Cost Of Revenue | 3.8B | 4.8B | 11.1B | 11.7B | 13.0B | 7.1B | |
| Income Before Tax | 878.4M | 1.1B | 1.4B | 1.4B | 1.8B | 1.1B | |
| Net Income | 652.5M | 802.2M | 976.7M | 1.1B | 1.3B | 778.9M | |
| Income Tax Expense | 225.9M | 267.9M | 385.8M | 369.6M | 469.3M | 283.3M | |
| Tax Provision | 225.9M | 267.9M | 385.8M | 369.6M | 469.3M | 316.8M | |
| Net Interest Income | (20.1M) | (29.9M) | (126.6M) | (223.2M) | (193.7M) | (184.0M) | |
| Interest Income | 15.4M | 42.7M | 40.7M | 25.2M | 29.0M | 24.9M |
Rossari Biotech Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Rossari Biotech. It measures of how well Rossari is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Rossari Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Rossari had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Rossari Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (37.7M) | (320.3M) | (481.9M) | 7.3M | (938.5M) | (891.6M) | |
| Investments | (1.2B) | 195.3M | 799.6M | (1.8B) | (1.0B) | (980.5M) | |
| Change In Cash | 234.7M | (140.0M) | 222.7M | 323.6M | (440.3M) | (418.3M) | |
| Net Borrowings | (164.2M) | 628.9M | (610.1M) | (48.1M) | (43.3M) | (45.5M) | |
| Free Cash Flow | (211.4M) | (103.2M) | (88.7M) | 1.2B | (880.3M) | (836.3M) | |
| Depreciation | 168.5M | 228.3M | 480.6M | 629.3M | 603.9M | 320.2M | |
| Other Non Cash Items | 20.1M | (12.7M) | 85.9M | 197.9M | 81.1M | 53.1M | |
| Dividends Paid | 105.9M | 26.5M | 25.4M | 27.5M | (27.6M) | (26.2M) | |
| Capital Expenditures | 759.7M | 580.8M | 382.3M | 328.8M | 1.3B | 1.4B | |
| Net Income | 880.6M | 1.1B | 1.4B | 1.4B | 1.3B | 991.1M | |
| End Period Cash Flow | 292.1M | 152.1M | 374.8M | 698.3M | 251.7M | 254.9M | |
| Change To Netincome | 18.4M | 57.9M | (69.8M) | (33.8M) | (30.4M) | (28.9M) |
Rossari Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rossari Biotech's current stock value. Our valuation model uses many indicators to compare Rossari Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rossari Biotech competition to find correlations between indicators driving Rossari Biotech's intrinsic value. More Info.Rossari Biotech Limited is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.56 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Rossari Biotech Limited is roughly 1.80 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rossari Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rossari Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rossari Biotech Systematic Risk
Rossari Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rossari Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Rossari Biotech correlated with the market. If Beta is less than 0 Rossari Biotech generally moves in the opposite direction as compared to the market. If Rossari Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rossari Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rossari Biotech is generally in the same direction as the market. If Beta > 1 Rossari Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Rossari Biotech Limited Total Assets Over Time
Rossari Biotech Thematic Clasifications
Rossari Biotech Limited is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Rossari Biotech November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rossari Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rossari Biotech Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rossari Biotech Limited based on widely used predictive technical indicators. In general, we focus on analyzing Rossari Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rossari Biotech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 8.01 | |||
| Value At Risk | (3.64) | |||
| Potential Upside | 2.56 |
Complementary Tools for Rossari Stock analysis
When running Rossari Biotech's price analysis, check to measure Rossari Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rossari Biotech is operating at the current time. Most of Rossari Biotech's value examination focuses on studying past and present price action to predict the probability of Rossari Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rossari Biotech's price. Additionally, you may evaluate how the addition of Rossari Biotech to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |